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Abstract
Background: Mucins are large O-linked glycosylated proteins which give mucus their gel-forming properties. There
are indications that mucus and mucins in saliva, breast milk and in the cervical plug inhibit the human
immunodeficiency virus (HIV-1) in an in vitro assay.
Main body of abstract: Crude mucus gels form continuous layers on the epithelial surfaces of the major internal
tracts of the body and protect these epithelial surfaces against aggressive luminal factors such as hydrochloric acid
and pepsin proteolysis in the stomach lumen, the movement of hard faecal pellets in the colon at high pressure,
the effects of shear against the vaginal epithelium during intercourse and the presence of foreign substances in the
respiratory airways. Tumour-associated epitopes on mucins make them suitable as immune-targets on malignant
epithelial cells, rendering mucins important as diagnostic and prognostic markers for various diseases, even
influencing the design of mucin-based vaccines.
Sub-Saharan Africa has the highest prevalence of HIV-AIDS in the world. The main points of viral transmission are
via the vaginal epithelium during sexual intercourse and mother-to-child transmission during breast-feeding. There
have been many studies showing that several body fluids have components that prevent the transmission of HIV-1
from infected to non-infected persons through various forms of contact.
Crude saliva and its purified mucins, MUC5B and MUC7, and the purified mucins from breast milk, MUC1 and MUC4
and pregnancy plug cervical mucus (MUC2, MUC5AC, MUC5B and MUC6), inhibit HIV-1 in an in vitro assay. There
are conflicting reports of whether crude breast-milk inhibits HIV-1 in an in vitro assay. However studies with a
humanised BLT mouse show that breast-milk does inhibit HIV and that breast-feeding is still advisable even
amongst HIV-positive women in under-resourced areas, preferably in conjunction with anti-retroviral treatment.
Conclusion: These findings raise questions of how such a naturally occurring biological substance such as mucus,
with remarkable protective properties of epithelial surfaces against aggressive luminal factors in delicate locations,
could be used as a tool in the fight against HIV-AIDS, which has reached epidemic proportions in sub-Saharan
Africa.
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The hydrochloric acid in the mammalian stomach is con-
centrated enough (pH 1–2) to digest the stomach [1], a
finding made by René Antoine Ferchault de Réaumur in
the eighteenth century [2]. However the epithelial lining of
the stomach remains intact during the digestive process
despite the potency of the acid, pepsin and shear associated
with digestion [3, 4], behaving, according to Claude
Bernard, as if the stomach was made of porcelain [2]!
In 1959 Heatley [5] proposed that mucus on the gas-
tric mucosal surface acted as a mixing barrier and postu-
lated the existence of a pH gradient from the lumen
(acid) to the mucosal surface (neutrality). This barrier,
later known as the mucus-bicarbonate barrier [3, 6]
allowed a restricted mixing of hydrogen and bicarbonate
ions [6], in a stable unstirred layer of variable thickness
in humans between 50 and 540 μm (mean 180 μm) [7].
The epithelial surfaces of the major internal tracts of the
body are protected by a continuous layer of crude mucus
gel. The main gel-forming component of the crude
mucus gels are mucins (mucous glycoproteins).
Ever since Fultz reported in 1986 [8] that saliva displayed
anti-HIV activity, explaining the reason for an absence of
transmission of the virus through the exchange of oral
fluids [9], it was speculated that a large macromolecular
component in saliva, such as salivary mucin, could be
responsible for the neutralization of the virus in the oral
cavity [10–12]. Further work with crude saliva and its saliv-
ary mucins suggested that mucins inhibited HIV-1 in an in
vitro assay [13–16]. Anti-HIV activity was also displayed by
non-mucin components of saliva such as salivary agglutinin
[17] A further investigation of purified mucins from bodily
regions of high transmission such as breast milk [18, 19]
and the cervico-vaginal area [20] showed that these mucins
too were potently anti-HIV-1.
The Human Immunodeficiency virus (HIV) is res-
ponsible for a worldwide pandemic, with sub-Saharan
Africa carrying the greatest burden of HIV-AIDS. There
are approximately 6 million people who are HIV posi-
tive over nine provinces in South Africa, with the most
number of cases in KwaZulu-Natal, followed by Gauteng
province (https://www.commerce.uct.ac.za/Research_Units/
CARE/RESEARCH/Papers/Indicators.pdf). Among South
Africans aged 15–24 years, 15% of young women and ap-
proximately 5% of young men are infected with HIV [21],
as compared with 1% of young women and men in the
USA [22]. Recent findings show that that women in sub-
Saharan Africa substitute penile-anal intercourse (PAI) for
vaginal sex for several reasons including as a means of
contraception, during menstruation, vaginal infections,
money and a belief that it will prevent HIV transmission
[23] Understanding risky habits around PAI, such as prom-
iscuity, transactional sex, sex under the influence of alcohol
and drugs and the non-use of condom-compatible lubri-
cants, is critical to addressing the spread of HIV and micro-
bicide development [24]. A study in South Africa has
shown that the prevalence of HIV infection in women
practising PAI was 61.3% compared with 42.7% of women
who did not have anal sex, a significant difference [25].
Whilst ongoing unpublished work in our laboratory
suggests that pig gastrin mucins (Muc5ac and Muc6)
inhibit HIV-1 in an in vitro assay, there is no information
in this regard of MUC2/Muc2, the main gel-forming
mucin of the lower bowel.
REVIEW (Main Text).
Mucus
Crude mucus is a complex secretion of primarily water
but also proteins, lipids, nucleic acids, cell debris, ions
and mucins, to which the stickiness and gel-forming
properties of the secretion are attributed [26–29]. It is a
visco-elastic secretion, usually continuous over gastro-
intestinal surfaces [7, 27], with both semi-solid and flow
properties, and can reform when sectioned and flow
over a relatively long time scale (30 to 120 min) [28–30].
The stickiness of the mucus gel ensures that the gel
adheres to mucosal surfaces, providing a slimy coat, for
example in the gut, where it facilitates the passage of
solid material, whilst protecting the mucosal lining from
injury and dehydration [28], and being a platform for the
support of a host of antimicrobial molecules [31].
The gastric gel is readily permeable to both H+ and
HCO3
− and provides an unstirred layer on the mucosal
surface in which the HCO3
− is secreted by the epithelial
cells and is prevented from mixing with the bulk of the
acid. Luminal acid is therefore neutralised before it
reaches the mucosal cells [3]. Whilst permeable to low
molecular weight solutes [32], the gel is impermeable to
larger molecules such as pepsin, microbes [33] and cer-
tain viruses such as human papilloma virus and Merkel
cell polyomavirus which are prevented from reaching
the underlying epithelial cells [34]. Pepsin however acts
on the luminal surface of the gel and hydrolyses poly-
meric mucins, liberating degraded mucin subunits into
the gastric lumen and causing a complete change in the
properties of the gel from an ‘elastic’ (semi-solid) state
to ‘viscous’ (liquid) state [35, 36]. Epithelial secretion
reinstates the gel to its original thickness, in a state of
dynamic equilibrium on the mucosal surface.
Purified mucins have been shown to form a gel in
solution [37]. The average concentration of mucin in pig
gastric mucus isolated directly from the stomach is
approximately 30–40 mg ml−1. Molecular interactions
between mucins have been shown to occur in this range
[37] contributing to a sharp increase in viscosity beyond
a glycoprotein concentration of 20–30 mg ml−1 and an
intrinsic viscosity of 320 ml g-1, suggesting an overlap of
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individual mucins in solution beginning at 20–25 mg ml−1
and resulting in the formation of a gel comprising
highly expanded solution-filling mucin macromolecules
[27, 37, 38], with an additional contribution through
non-covalent interactions [37] by the inter-digitation of
oligosaccharide chains of the mucins, involved in the
formation of the gel network and contributing to the
effectiveness of the gel [27]. Thinner gels of lower
viscosity [38, 39], for example in the stomach, report-
edly have an increased content of subunit in relation to
polymer, and have been shown to be associated with
diseases such as gastric ulceration [40, 41], and carcin-
oma of the stomach [42]. Non-mucin proteins such as
trefoil factor (TFF2) have been shown to be physically
attached to and strengthen gastric mucus gels, also
inhibiting the permeation of H+ ions through the gel
[43, 44]. It is likely that non-mucin proteins that
contribute to epithelial protection such as secretory
IgA, lysozyme, gp340 and calcium play a key role in
mucus organization [16, 45].
The mucus secretion coats the surfaces of the gastro-
intestinal, cervical and respiratory tracts [28] as well as the
oral cavity [46]. Besides acting as a lubricant on epithelial
surfaces, versatility and specialization are features of mucus
[47]. The mucus gel barrier on the mucosal surface of the
stomach protects it from the shear forces associated with
digestion and the potency of hydrochloric acid and pepsin
[4, 5]. The muco-ciliary blanket of the respiratory airways
protects the alveoli by trapping inhaled dust particles and
other foreign impurities which are then removed by swal-
lowing [48]. Colonic epithelium is shielded from hard faecal
materials and bacteria by a continuous layer of mucus on
the mucosal surface [49, 50]. The mucus plug at the mouth
of the cervix protects against the entry of bacteria and facil-
itates the movement of sperm during the mid-cycle [51].
Saliva aids in the lubrication and homogenization of
chewed food [52] and gallbladder mucus protects the
underlying epithelium against a concentrated mixture of
surface-active chemicals [53].
In each instance, the general but variable properties of
mucus are exploited differently to fulfil the special func-
tion that is required [47]. Adherent mucus is a ‘true’ gel,
that is, it does not dissolve on dilution, even by exposure
to denaturants, salts, acid or detergents [54]. Such gels
sediment by centrifugation and have cyto-protective prop-
erties of an unstirred layer on epithelial surfaces [55].
Mucus layers form an ecological niche for microbiota in
the various major internal tracts of the body. Microbes in
the mucus gel will be constrained, thus being unable to
have interactions such as cell-to-cell communications and
inter-species competition [56]. It is also becoming apparent
that mucus in the gut is critical to the maintenance of a
homeostatic relationship between the gut microbiota, com-
mensal flora dominated by Fermicutes and Bacteriodetes
[57], and their hosts. Deviations from this dynamic
interaction have major implications for health, among
which are colitis, colorectal cancer and susceptibility to
infection [58]. Some gut bacteria have the ability to forage
on glycans of the oligosaccharide chains made available by
mucins in the gel [59].
Mucins (mucous glycoproteins)
There are two types of mucins, the secreted [28] and the
trans-membrane types [60, 61] types. Evidence suggests
that mucin-type O-glycosylation is essential for normal
development [62], playing important roles in protein
secretion, stability, processing and function, whilst
aberrations of O-glycosylation are responsible for certain
human diseases and disease susceptibilities [63], with
associated modifications in the properties of the mucins
[64]. The 4 major secreted gel-forming mucins, which
share a common evolutionary ancestor, are MUC5AC in
the stomach [65] and airways [66], MUC5B, also in the
airways [67] and gall-bladder [68], MUC2 in the colon
[69] and MUC6, again in the stomach [70], the genes of
which are clustered on chromosome 11p15.5, whilst the
gene for the fifth gel-forming mucin, MUC19, is on
chromosome 12 [71]. There is a large family of trans-
membrane mucins, of which MUC1 and MUC4 play an
important biological role in cell-cell and cell-
extracellular matrix interactions, in cell signalling and in
the biological properties of cancer cells [72]. Currently,
the most widely used biomarker for ovarian cancer is
MUC16 (CA125), a large transmembrane mucin [73, 74]
the levels of which are elevated in 80–90% of patients
with advanced ovarian carcinoma. MUC16 lines the
endocervix, endometrium, and fallopian tubes to provide
an additional barrier to pathogens, preventing them
from reaching the epithelium. The endocervix is lined
by a single layer of columnar epithelial cells that is
highly susceptible to infection by HIV and the MUC16
barrier provides an additional protective layer against in-
fectious agents [75–77]. One study reported that the epi-
demic disease-causing S. pneumoniae species secretes a
metalloproteinase, ZmpC, which selectively induces
ectodomain shedding of the MUC16, the first line of de-
fence for epithelia in the eye, causing conjunctivitis [78].
MUC16 has been shown to have an enhanced binding
of IgG antibodies generated during chronic HIV
infection [76]. This interaction between antibodies and
MUC16 has potential to concentrate HIV-specific anti-
bodies within the glycocalyx covering the luminal sur-
face of the endocervix, thus enhancing mucosal barrier
function and having implications for the design of the
next generation vaccines and microbicides [76].
Changes in the sequence of glycosylation of mucins in
different settings generate a variety of epitopes in the
oligosaccharide side-chains of mucins, including newly
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expressed blood-group antigens, distinguishing between
normal and diseased states. Tumour-associated epitopes
on mucins and their antigenicity make them suitable as
immuno-targets on malignant epithelial cells and their
secretions, creating a surge of interest in mucins as diag-
nostic and prognostic markers for various diseases [79], and
even influencing the design of mucin-based vaccines [80].
It is known that oncogenic changes are associated with
changes in glycosylation in glycoproteins and glycolipids
[81], generating new antigens exploitable as laboratory
diagnostic markers, amongst which are T, Tn and sialyl-Tn
antigens, in a variety of cancers [82]. The sialyl-Tn epitope
is one of the most specific tumour antigens described so
far, being highly expressed on many adenocarcinomas but
having a very limited expression in normal adult tissues
[83]. Its expression on mucins in the non-dysplastic colonic
mucosa of long-standing ulcerative colitis patients identifies
an increased cancer risk [84]. A variety of epitopes are
expressed on the mucin oligosaccharide chains, glycan mo-
tifs that can be recognised by bacterial adhesins and lectins
[85] and a host of mucin-microbe interactions have been
reported [86]. Adhesins allow for interactions between viral
haemagglutinins and terminal sialic acid residues in mucins.
Salivary and respiratory mucins in cystic fibrosis have mod-
ifications of their carbohydrate side-chains that increase
their binding affinity for Pseudomonas aeruginosa [87]. It is
likely that the primary function of the oligosaccharide di-
versity in mucins, for example in the respiratory airways, is
to enhance the possibility that bacteria bind to mucus, thus
facilitating their removal by mucociliary transport. Mucins
provide competing receptors for cell-surface glycoconju-
gates, in this way trapping bacteria and preventing them
from colonizing the epithelia [31, 88].
Many monoclonal antibodies reactive with cancers de-
tect mucin carbohydrate determinants which on malig-
nant cells are associated with cancer aggressiveness and
metastasis. Some of these epitopes are cryptic but can be
exploited by directing immunotherapy against them,
since they are potentially immunogenic and can stimu-
late humoral and cellular immune responses in cancers
and perhaps HIV-AIDS? One such antigen is the Thom-
sen-Friedenreich (TF) antigen, found on mucins and which
was reported to protect against a lethal TA3-Ha tumour
transplant in mice [89].
In the human stomach alone more than 70 different
oligosaccharides are carried by mucins, mostly neutral and
highly fucosylated, with less sialyated and no sulphated
groups, suggesting an enormous diversity in a single organ
[90]. Helicobacter pylori is a known causative agent for
chronic active gastritis, ulceration and carcinoma of the
stomach [91]. It is found within the mucus gel, where its at-
tachment is mediated by the Lewisb antigen in MUC5AC,
and it is also attached to mucosal epithelia. Sialic acids,
found both in mucins and on the epithelial surface, seem to
be the favoured binding site of various viruses such as
influenza viruses, reoviruses and adenoviruses [92]. It is ap-
parent that mucin glycans, their length, composition and
sequences are subject to alterations in different environ-
mental conditions [93], during which they may be either
protective by binding and retarding the movement of these
organisms through the gel towards the epithelia [34], or
they may succumb to infection.
Components of saliva
An amount of approximately 1500 ml of saliva [94], a
dilute aqueous secretion which contains 99% water,
mucins, lipids, and proteins [46, 95, 96] is produced
daily by the submaxillary, sublingual and parotid glands
[97]. Saliva lubricates and cleanses the oral cavity [98],
provides an innate immune defense against pathogens
[99] and plays an important role in the aggregation and
clearance of micro-organisms, including HIV [100, 101].
Most of the anti-bacterial proteins in saliva also display
anti-viral activity [102]. Oral transmission of HIV by
exchange of oral fluids is a rare event, even in cases of
bleeding and the presence of exudate in the oral cavity.
Only 1–5% of an HIV - positive patient’s saliva contains
infectious HIV despite there being higher levels in the
blood. It is thought that hypotonic disruption may be a
major mechanism by which saliva kills infected
mononuclear leukocytes and prevents their attachment
to mucosal epithelial cells and production of infectious
HIV, thus preventing transmission [9]. Any remaining
infectious HIV will have to be inhibited by salivary
components, the search for which began in the 1980s.
The recent concept of salivaomics, a broad collection of
technologies investigating salivary constituents and their
roles in saliva, encompasses genomics, transcriptomics,
proteomics, metabonomics and microbiota studies, with
saliva having applications in early diagnosis of diseases, and
in translational and precision medicine [97, 98]. A consor-
tium of three research groups identified 1116 proteins in
saliva, a high proportion of which were found in plasma
and tears [103] making saliva an excellent substitute for
blood as a diagnostic fluid, easy to collect repeatedly, non-
invasively, and with the opportunity of multiple sampling
by patients themselves, thus reducing clinical costs and in-
creasing patient compliance [104].
Salivary mucins
Human saliva was originally reported to contain two
carbohydrate rich mucin populations, namely MG1
encoded by the MUC5B gene and MG2, encoded by the
MUC7 gene [105]. These mucins, synthesized by different
cells of the salivary glands [94], are reported to differ
structurally and functionally [67, 68] and are separable by
Sepharose 4B gel filtration [13, 95, 105].
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MUC5B [105–107] is one of the most widely distrib-
uted mucins found in saliva and the respiratory and
female reproductive tracts. Secreted by all the salivary
glands except the parotid, MUC5B is known to contain
19% protein and 81% carbohydrate [107, 108]. Salivary
MUC5B is a large, polymeric disulphide bonded secreted
mucin with a complex structure [83], the carbohydrate
moiety of which is reported to aggregate and clear
bacterial, fungal and toxic pathogens from the oral cavity
[96, 103, 105], and to inactivate HIV [13]. It is conceivable
that large disulphide-bonded mucin polymers which form
non-covalent interactions through the inter-digitation of
their densely packed oligosaccharide side-chains [27]
result in the formation of a network that surrounds mi-
crobes thus restricting their movements. It is not known
how these constraints influence microbial interactions,
such as cell-to-cell interactions and competition among
the vast number of organisms that live in mucus [56]. In
the case of microbiota in the oral cavity, salivary MUC5B
affects intra-species interaction by promoting dispersal of
bacteria and fungi. In an experimental, dual-species model
Frenkel and Ribbeck [56] very recently showed that mucins,
in this case salivary MUC5B, promoted the coexistence of
two competing bacteria, S. sanguinis and S. mutans,
perhaps by promoting a less competitive mode of growth
between them.
MUC7 [106] is found in saliva [107] and together with
MUC5B in the bronchus [109]. Salivary MUC7, the
smallest of the secreted mucins, is a non-gel forming,
less heterogeneously glycosylated mucin [110] secreted
by the submandibular, sublingual and palatine salivary
glands [111]. MUC7 is reported to contain 30% protein
and 68% carbohydrate [108, 111]. Thus far two glycoforms
of MUC7 namely MUC7a and MUC7b with similar amino
acid but different sialic acid and fucose compositions are
reported to exist in human saliva [107, 112]. MUC7 is
reported to possess inhibitory activity against a number of
bacterial, fungal and viral strains including Streptococci,
P.aeruginosa, S. aureus, C. albicans and S. cerevisiae,
amongst others [13, 112–114]. It also plays a crucial role in
the inhibition of HIV transmission through saliva [10, 13].
A gene for a putative polymeric mucin, MUC19, reported
as a fifth human gel-forming mucin, has been shown to be
expressed in human salivary glands [71]. Rousseau et al.
[52] showed that there was no evidence for MUC19 in
human saliva, a finding confirmed in our laboratory
(Santhoshan Pillay, personal communication), suggesting
that MUC19 is not a major component in human saliva.
Anti-HIV activity of human saliva
The idea that incubation of HIV with saliva decreases
HIV activity was first suggested by Fultz in 1986 [8],
who showed that whole saliva and saliva filtrates inhibit
HIV. For complete inhibition to occur, virus and saliva
had to be incubated together for more than 30 min. This
finding led to more investigations by various groups to
identify the factor/s in saliva responsible for the inhib-
ition of HIV. Whole saliva and equal volumes of HIV-1,
when filtered through 0.45 μm Nalgene filters, showed
no toxicity to phytohemagglutinin – activated normal
peripheral blood lymphocytes and showed inhibition of
infection of these lymphocytes [10]. They further showed
that the inhibition was also by submandibular secretions
and not those of the parotid gland, a finding confirmed
by Archibald and Cole [11]. Filtration studies using
whole saliva and an HIV-1/ATH8-cell cytopathic system
and the monitoring of inhibitory activity by viable cell
counts and HIV-1 core antigen and reverse transcriptase
levels, showed approximately 50% less virus than in
HIV-1/media filtered controls, suggesting that inhibition
was caused by aggregation of the virus by an unknown
salivary component [115]. Filtration of whole saliva and
human submaxillary and sublingual (HSMSL) saliva
through a 0.22 μm pore size filter, prior to addition of
the virus showed far less inhibition of HIV-1 in the fil-
trate as compared to the virus being incubated with sal-
iva prior to filtration [116]. It was Malamud et al. in
1993 [100] who reported that the major anti-HIV activity
in saliva resided in the submandibular secretion in which
inhibition is seen in 2 min and increased with time. This
inhibitory activity was specific for HIV and shows no ef-
fect on HSV and adenovirus. Electron microscopic stud-
ies showed that HIV-saliva aggregates were trapped in
0.45 μm pore size nitrocellulose filters suggesting that hu-
man submandibular saliva aggregates HIV [100, 117]. Robi-
novitch et al. [118] submitted saliva in blinded fashion for
quantitation of their anti-HIV activity, using a syncytia-
forming MT-2 cell assay or the p24 antigen ELISA. Nine
out of the 27 subjects showed detectable anti-HIV infectiv-
ity activity. Parotid secretions in this study showed no in-
hibition and filtration of the saliva through an Amicon 10
filter before incubation with the virus once again abolished
inhibitory activity. Similar studies using two other bio-
logical fluids, urine and cerebrospinal fluid, revealed no
anti-HIV infectivity activity. These findings confirm the
presence in saliva of inhibitory activity directed toward
HIV by an unknown component, again in whole saliva
and by inference, submandibular secretions [118].
The suggestion that mucins could be the anti-HIV factor
was first made by Bergey et al. [119], who fractionated
human submaxillary/sublingual saliva (HSMSL) and dem-
onstrated anti-HIV activity in mucin-rich fractions. Electron
micrographs revealed an association of viral particles with
salivary sediment, again suggesting an aggregation of virus
by salivary components, whilst gel filtration studies showed
that inhibition was associated with mucin-rich fractions of
saliva. Shine et al. [12] reported that viral p24 and HIV-1
RNA were detected in tonsils and adenoids of
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asymptomatic seropositive individuals and yet the infectiv-
ity of whole saliva, that from the HSMSL, and less so the
parotid glands, reduced HIV-1 infectivity in vitro. Malamud
et al. [120] suggest that multi anti-viral activities are present
in saliva, working separately or together to reduce HIV in-
fectivity, the effect of which is directly on the virus rather
than the infected host cell. Salivary agglutinin [120, 121],
secretory leukocyte protease inhibitors (SLPI) [122] and
proline-rich proteins [118, 123], are examples of such anti-
HIV factors in saliva [11]. The study of Baron et al. [9]
strengthened this multi anti-viral idea by adding the hypo-
tonic nature of saliva which causes the disruption of in-
fected leukocytes, perhaps producing free virus into the
oral cavity to be acted upon by other protective factors such
as salivary mucins, further reducing any chance of trans-
mission through exchange of oral fluids. Nagashunmugam
et al. [14] reported that though the level of anti-HIV-1 ac-
tivity was higher in submandibular than parotid or whole
saliva with or without filtration (in 9/15 cases), there was
some inter-individual variation in that 4/15 showed lesser
inhibitory activity, and 2/15 none at all except after filtra-
tion. They went further to show that saliva rendered
HIV-1 harmless by stripping gp-120 from the virus,
with partial purification by anion – exchange chroma-
tography revealing two high - molecular – weight sia-
lyated glycoproteins, salivary agglutinin and mucin as
the possible factors of inhibition of HIV [15]. Further
studies confirmed that whole saliva and individual secre-
tions of submandibular and sublingual but not those of
the parotid glands (which lack mucin) [94, 124, 125], are
inhibitory, suggesting that the virus is rendered harmless
when bound to a high-molecular weight salivary compo-
nent, the complex being separable by filtration [11, 12, 14,
15, 100, 122, 125]. Bergey et al. in 1994 [119] demon-
strated a maximum anti-HIV-1 activity of the mucin - rich
fractions of human submandibular saliva. This reduces
the risk of the transmission of HIV through the oral route,
raising questions about the specificity of inhibition in the
oral cavity [9, 12, 100, 101, 119]. The detection of HIV in-
fection with an oral fluid-based (saliva) rapid and accurate
point-of-care test is already a reality [126].
Work in our laboratory confirmed the anti-HIV-1 activity
of crude human saliva and its purified mucins MUC5B and
MUC7 from uninfected individuals [13, 16, 127] by in vitro
assays, according to the method of Nagashunmugam et al.
[14]. The virus used in the assay was first isolated and fully
characterized and sequenced in the Department of Medical
Virology, University of Stellenbosch in February 1986
(CdB) [13, 128]. Habte et al. [128] further showed that
MUC5B and MUC7, purified from the saliva of infected
individuals of different CD4 counts (< 200, 200–400 and
>400) did not inhibit the virus in an in vitro assay. Saliva
and purified salivary mucins were incubated with HIV-1
prior to infection of the human T lymphoblastoid cell line
(CEM SS cells), after which viral replication was measured
by a p24 antigen assay. This finding was subsequently re-
futed by Peacocke et al. [16] in a wider study, and one
which was a slight variation of the Nagashunmugam et al.
[15] assay, comparing samples from HIV positive and
negative individuals, incubated with subtype C HIV-1 and
infection of peripheral blood mononuclear cells (PBMCs)
[16]. Peacocke et al. [16] reported that crude saliva and its
salivary mucins from both uninfected and HIV positive
individuals inhibited, HIV-1 in an in vitro assay.
Breast milk components
Human breast milk is the culmination of 200 million
years of Darwinian pressure on mammalian lactation as
the sole source of early infant nourishment [129].
Human milk is an excellent example of a mutual and
beneficial relationship of humans and microorganisms,
contributing to both acute survival and long-term health
of humans and ensuring the selective colonization and
support of a protective microbiota [129]. The most
abundant component of human milk are lactose, lipids
and 200 molecular species of oligosaccharides, the latter
being indispensable for the nourishment of the infant’s
microbiota, the general growth of the infant, the stimu-
lation and modulation of its immune system, cognitive
development and protection from toxins and disease.
The oligosaccharide population is remarkably diverse and
displays an inter-individual variation during lactation
amongst feeding mothers [129]. Human breast milk is also
reported to contain a number of non-immunological
components such as glycolipids, glycoproteins, mucins
and glycosaminoglycans [130–133] and proteins which
include lysozyme and β-casein [131]. These components
are biologically active and protect breast fed infants
against harmful microbes, viruses, and toxins [130, 132],
including the inhibition of rotavirus and S-fimbriated E.
coli by milk mucin, inhibition of cholera and labile toxins
of E. coli by milk glycolipids [133], inhibition of S.
pneumoniae, H. influenzae and entero-pathogenic E.
coli adherence by human milk oligosaccharides [134]
and quite recently, neutralization of HIV-1 by tenascin-
C [135]. Breast milk components are also reported to
inhibit pathogens such as hepatitis C, Ebola, cyto-
megalovirus, Dengue virus, M. leishmania, C. albicans,
and H. pylori [131, 132].
Human breast milk mucin
Human milk contains well characterised MUC1 [136]
and MUC4 [137], both trans-membrane mucins [138],
which are components of the milk fat globule membrane
[130, 139]. MUC1, which is located on chromosome
1q21-q24 [140], is the most widely distributed human
mucin and is expressed in the mammary gland, lungs,
pancreas, gastrointestinal tract, kidney, bladder,
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endometrium, ovary and testes [141]. It has 25 to 125
tandem repeats and has a molecular weight between 250
and 1000 kDa [141, 142], with carbohydrate comprising
50% of its weight [143].
MUC4 is expressed in the ciliated and goblet cells of
the epithelial tissues of the stomach [144], breast,
endocervix, colon [145], uterus, ovary, salivary gland,
prostate, thyroid, mammary gland, esophagus, testis and
placenta [106] and tears [146]. Beyond the respiratory
tract, MUC4 has been reported to be a novel prognostic
factor in patients with invasive ductal carcinoma of the
pancreas and chronic pancreatitis [147, 148], intra-
hepatic cholangiocarcinoma-mass forming type [149],
extra-hepatic bile duct [150] and lung adenocarcinoma
[151] and, unlike MUC1, is not associated with metasta-
sis in cholangiocarcinoma [152].
Anti-HIV activity of breast milk and its mucins
There have been contradictory findings with respect to
the capacity of breast milk to inhibit HIV-1. A study by
Wahl et al. [153] suggested that prior to their work,
breast milk studies in relation to HIV inhibition were in
vitro studies which all showed milk to have a strong in-
hibitory effect on HIV infectivity. However Habte et al.
[18] showed that crude uninfected breast milk, did not
inhibit HIV-1 in an in vitro assay, a finding confirmed
by Mthembu et al. [19] for both HIV negative and HIV
positive milk, in our laboratory. Purified MUC1 isolated
from the breast milk, inhibited HIV-1 [18]. Another
study by Newburg et al. in 1992 [154], found breast milk
from both HIV positive and negative patients to contain
an HIV-inhibitory factor, not present in bovine milk or
human sera, that inhibited the binding of HIV epitope-
specific MAb to recombinant CD4 receptor molecule, and
which lost its potency upon destruction of sulphate mole-
cules, suggesting it could be a mucin.
On the other hand Kazmi et al. (2006) [155] demon-
strated high levels of anti-HIV-1 activity by crude breast
milk comparable to that of saliva. It was also found that
breast milk obtained from uninfected women had a
primary HIV-1 neutralizing protein, tenascin-C, which
captures and neutralises HIV-1 by binding to the chemo-
kine co-receptor binding site on the HIV-1 envelope, is an
extracellular matrix protein important in foetal develop-
ment and wound healing [135]. The complexity of this
issue is highlighted by the finding of Lyimo et al. [156] that
breast milk may provide a protective function against cell-
free HIV-1 but may be less effective at blocking infection
by cell-associated virus. When human milk was inoculated
with cell-free and cell-associated HIV-1 and subsequently
heated and pasteurised, both forms of the virus were
inactivated [157].
Furthermore, in the absence of anti-retroviral prophy-
laxis, greater than 90% of infants exposed to HIV-1
breast-feeding remain uninfected, despite daily mucosal
exposure to the virus for up to 2 years [135]. It is known
that despite the nutritional and health benefits of breast
milk and its protective role against a variety of patho-
gens [158], breast milk can serve as a vector for mother-
to child HIV transmission [159], with reports that breast
feeding was responsible for about 30–50% of approxi-
mately 500,000 infant HIV-1 infections worldwide
around the turn of the century [158, 159], or generally at
rates of 20–50% [154].
Although HIV-1 is inhibited by saliva [13, 16] it is
shown that the saliva of the infant is overwhelmed by
the viral load in the milk of the mother during breast
feeding [160]. Human breast milk has a high titre of
viable virus ranging from 240 to 8100 copies/ml, com-
pared with less than 1 copy/ml in saliva [156]. However
there is still a case for breast-feeding as opposed to
replacement feeding by using antiretroviral drugs and
shortened breastfeeding, which markedly decrease
breastfeeding HIV-1 transmission, shifting the balance to
make replacement feeding less beneficial [159, 160].
The paradoxes in the findings mentioned above could
complicate the well-established notion of ‘breast-is-best’,
especially in the context of an HIV pandemic in resource
limited settings such as in sub-Saharan Africa. It is
known that most HIV-infected infants acquire HIV
through breastfeeding, over and above infection in utero
and during labour and birth. However, most breastfed
infants remain uninfected despite prolonged and
repeated exposure to HIV. All this suggests that breast
milk in relation to HIV has contradictory roles, provid-
ing protection or is a risk for infection [153].
Wahl et al. [153] saw the necessity of examining the
inhibitory effect of breast milk in an in vivo humanized
(BLT) mouse model of oral HIV transmission. They showed
that breast milk has a strong inhibitory effect on oral trans-
mission of cell-free and cell-associated HIV. Furthermore
anti-retrovirals administered prior to oral transmission of
HIV prevented transmission in BLT mice.
The WHO in 2014 reported that an estimated 240,000
children become infected with HIV annually through
breastfeeding but still advised that in resource-limited
settings (which sub-Saharan Africa and Southern Africa
are), mothers should still breastfeed, in combination
with infant or maternal antiretroviral therapy, because
the health benefits of breastfeeding far outweigh its risks
[160]. Most infants breastfed by HIV positive women do
not become infected, even when fed HIV positive milk
[160]. They further showed that the amazing anti-HIV
properties of breast milk inhibit other modes of infec-
tion, preventing multiple routes of infection, for example
preventing vaginal transmission [160].
Both Habte et al. [18] and Mthembu et al. [19] speculated
that crude breast milk did not inhibit HIV-1 in vitro
Mall et al. Virology Journal  (2017) 14:192 Page 7 of 14
because of the membrane-bound nature of breast milk
mucins, which are enclosed in fat globules, thus preventing
contact between the virus and the mucin. Purified MUC1,
when isolated from crude normal breast milk after delipida-
tion inhibited HIV-1 [18] and showed anti-poxvirus activity
[138], both in an in vitro assay. It has also been shown that
MUC1 prevented DC-SIGN-mediated transmission of
HIV-1 from dendritic cells to CD4+ T cells [160]. A follow-
up and broader study in our laboratory by Mthembu et al.
[19] comparing the inhibitory potential of normal milk and
milk infected with HIV-1, showed that crude human breast
milk from both HIV positive and HIV negative patients did
not inhibit HIV-1, whilst its purified mucin components
(MUC1 and MUC4), from normal and infected milk, did.
More studies would be required to clarify the differences in
these findings.
Cervical mucus
Cervical mucus is known to play a crucial role in human
reproductive physiology by providing lubrication for and
the prevention of the desiccation of the vaginal mucosa
[161–164] preventing microbial colonization, fluid loss
and the control of sperm survival and migration to the
upper reproductive tract [163, 165–167]. According to
Yurewicz and Moghissi [168], cervical mucus facilitates
the movement of sperm to the upper reproductive tract
during the mid-cycle and, under the influence of
oestrogen, selectively excludes abnormal and poorly mo-
tile sperm cells. Mucus enhances the survival of sperm
by protecting it from phagocytosis [169] and the anti-
HIV activity of mucus is at its best at an acidic pH [170].
Despite the continuous change in mucus viscosity
throughout the menstrual cycle and the risk during the
proliferative phase of pathogen entry into the cervix, the
mucus clears millions of micro-organisms daily from the
female reproductive tract [171]. The cervical mucus plug
is a viscous gel both on the mouth of the cervix and in
the cervical canal, and which is released during labour
[20]. One study reported that the plug inhibits but does
not block the passage of Ureaplasma parvum when it
ascends from the vagina to the cervix [172]. It is thought
that the mucus barrier provides protection to the female
reproductive tract through a stable association between
IgG and IgA with cervical mucus and an association of
IgG only with cervicovaginal mucus [164]. Vaginal
microbiome dysbiosis is associated with HIV infection
and alterations in the levels of gel-forming mucins in the
vagina have been reported, with a significant increase of
MUC5B levels in a Lactobacillus crispatus environment
and a relative increase in MUC5AC in moderate and
severe dysbiosis, dominated by Lactobacillus iners [173].
There is a varying amount of mucus during the human
reproductive cycle, which is differentially abundant dur-
ing the oestrus (Day 0 of the cycle) and luteal phases
(Day 10), contributing to the varying viscosity of the
cervicovaginal fluid. The first physiological barrier the
spermatozoa encounters is the cervix with its vaginal
side covered by a highly viscous mucus, the cervical
vaginal fluid (CVF) [174]. The amount of CVF increases
at the time of ovulation concomitantly with a higher
state of hydration and a reduced viscosity, to facilitate
sperm migration [175]. The mechanical properties of the
mucus are essential to select spermatozoa with the
highest fertilizing ability, i.e. with normal morphology
and efficient mobility [176]. Thus, only a small percent-
age of normal spermatozoa will be able to cross the cer-
vical mucus and fill the lumen of the cervix. The
rheological properties of this mucus are known to
change along the cycle, with a reduced viscosity at
oestrus, to allow spermatozoa to reach the uterus, and
an increased viscosity during the luteal phase to protect
the uterus from external contamination [175]. The vis-
cosity of the cervical mucus is mainly due its high con-
tent of mucins, 5B and 5AC [177]. Gipson et al. [178]
using the MUC5B antibody along with a cervical mucin
standard cervical mucin isolate in enzyme-linked im-
munosorbent assay, showed that a peak of MUC5B
mucin in human cervical mucus collected at midcycle,
compared with mucus from early or late in the cycle.
This peak in MUC5B content coincides with the change
in mucus character that occurs at mid-cycle, suggesting
that this large mucin species may be important to sperm
transit to the uterus [178].
Anti-HIV activity of purified cervical mucins
Lai et al. [170] showed that CVF, obtained from donors
with normal lactobillus-dominated vaginal flora, effi-
ciently traps HIV, causing it to diffuse more than 1000
fold more slowly than it does in water. This is due to the
acidification of the mucus by Lactobacilli, which pro-
duce lactic acid which acts by abolishing the negative
surface charge on HIV without lysing the virus mem-
brane, and facilitating its entrapment in the mucus
[170]. In a study using human cervical explants and in
vivo exposure to HIV-1 in a rhesus macaque vaginal
transmission model, it was shown that HIV-1 diffuses
through the squamous epithelium, penetrating areas
where cell junctions were absent but unable to traverse a
mucus barrier to enter columnar epithelial cells [179].
Habte et al. [20] in our laboratory showed that the crude
cervical plug mucus obtained from uninfected mothers
prior to delivery, did not inhibit the virus in an in vitro
assay but the purified mucin from the same plug, did
[20, 127]. A study by Ghosh et al. (2010) [180] showed
that CVL secretions from HIV+ and HIV- women con-
tain innate and adaptive factors inhibiting the virus. Fur-
ther work in our laboratory showed that crude cervical
mucus from HIV positive and negative individuals did
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not inhibit the virus but their purified mucins did
(manuscript in preparation).
Chen et al. [181] hypothesised that reducing HIV
heterosexual transmission at the portal of entry would
be the best prevention strategy. Since the affinity of anti-
bodies for mucus is weak, they developed an in vitro
model in which multiple antibodies, binding to a single
virion at one time would increase the overall antibody-
mucin binding avidity, creating an inheritable virus-
mucin affinity. The model predicts that HIV-specific Ab
in cervico-vaginal mucus will lead to the formation of an
HIV concentration front near the semen/CVM interface,
away from the vaginal epithelium, thus minimizing the
risk of infection. This model they say is a first step to-
ward an improved quantitative understanding of the
dynamics of mucosal immunity in the female reproductive
tract and future improvements to the model model will
provide further predictive insights into reinforcing vaginal
mucosal immunity against HIV and other sexually
transmitted infections.
Possible applications of the role of mucus and mucins
against HIV-1
Work in our laboratory on the role of mucus and mu-
cins in HIV-AIDS suggest that crude saliva and purified
mucins from saliva [13, 16, 128], breast-milk [18, 19]
and the cervical plug [20] inhibit the HIV virus in an in
vitro assay and that it is the inhibitory properties of
these mucins in crude saliva that prevent the transmis-
sion of the virus during the exchange of oral fluids. The
visco-elastic and gel-forming properties of crude mucus
gels, which provide protection of epithelial surfaces
against hostile milieu in the major tracts of the body, are
due to their mucin content [35, 37] or an interaction be-
tween mucins and non-mucin protein [45]. Furthermore
mucins by themselves can form gels in vitro at concentra-
tions comparable to those in the physiological context [35].
Lieleg et al. [34], in a study of porcine gastric mucins,
suggested that these mucins might be suitable candidates
for supplements in personal hygiene products such as
mouth rinse, toothpaste and perhaps even a genital
paste, because of their anti-viral activity.
Efforts to elicit HIV glycan-dependent broadly cross-
neutralizing antibodies by vaccination have not been
successful [34]. Microbicides have been in development
for over two decades and early efforts in this regard
failed due to irritation of the vaginal epithelium and sub-
sequent inflammatory responses [182, 183]. Karim et al.
[184, 185] developed an antiretroviral microbicide,
Tenofovir gel providing proof of concept that such for-
mulations are possible in the fight against the AIDS
pandemic and the empowerment of women whose
vulnerability to infection in this situation is obvious. The
gel has been reported to reduce HIV acquisition by an
estimated 39% overall, and by 54% in women with high
gel adherence [184].
In the light of the sheer importance of continuing to
meet this challenge and the above-mentioned protective
properties of mucins together with their additional anti-
HIV-1 effects, we wondered whether mucins could be
exploited to formulate a biologically based biocompatible
substance that could act as a topical prophylactic to pre-
vent the transmission of the virus during vaginal and
anal sexual intercourse (see ref. [34]). The increase in
heterosexual anal intercourse reported in sub-Saharan
Africa [23–25] with the increased possibility of transmis-
sion of HIV via the anal route, has given the question of
microbicide development a greater urgency [186]. MUC2 is
the gel-forming mucus in the large bowel and its anti-HIV
properties have not as yet been studied and we plan to
embark on such a project in the near future. Further work
is required to elucidate the mechanism of the interaction
between mucin and HIV-1. Our studies and those of others
suggest a strong possibility that any interaction between
mucins from different areas in the body and HIV-1, would
take place at the oligosaccharide level. There is a huge
absence of carbohydrate research facilities in South Africa
generally and we are planning collaborative efforts with
groups overseas. Our focus would be on the sequences of
the mucin sugar side-chain that gives optimal binding and
inhibition of HIV-1. Thus far inhibition by salivary MUC5B
has shown great promise in this regard. Factors such as the
diurnal variation of mucus-mucin secretions and the health
and nutritional status of the donor will be taken into ac-
count during sample collection. We are currently working
towards comparing the anti-HIV potency of each of the
gel-forming mucins, individually and in various combina-
tions, which will provide the basis of our planned formula-
tion of a vaginal paste that will further fortify the vaginal
epithelium against infection during sexual intercourse. The
increase in penile-anal sexual intercourse among African
women raises questions about the role of the mucus gel
covering the gastrointestinal mucosa in this context. MUC2
is the gel-forming mucin in the lower bowel [24, 36] and
our aim to test individual mucins against HIV-1 will be
informative in this regard. Because of the difficulties of
accessing human material for our work, we have embarked
on another project to test the anti-HIV potency of mucus
material obtained from animal sources.
Conclusions
Whilst ongoing unpublished work in our laboratory sug-
gests that pig gastrin mucins (Muc5ac and Muc6) inhibit
HIV-1 in an in vitro assay, there is no information in
this regard of MUC2/Muc2, the main gel-forming mucin
of the lower bowel. Considering the high prevalence of
HIV-AIDS in sub-Saharan Africa and the changing sex-
ual practices such as PAI amongst certain groups, with
Mall et al. Virology Journal  (2017) 14:192 Page 9 of 14
their associated risk of more infections, we wondered
whether the gel-forming and protective properties of
mucus, together with suggestions of the anti-HIV activ-
ity of mucins, could be exploited in the formulation of a
mucus-based microbicide? This would help serve to for-
tify existing mucus gel linings in the vagina and anus to-
gether with providing a scaffolding for smaller molecules
with anti-HIV properties, to reduce the risk of infection.
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